{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:58:44Z","timestamp":1793609924377,"version":"4.5.0"},"reference-count":74,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Chemotherapy-induced peripheral neuropathy (CIPN) is a substantial adverse effect of anticancer treatments. As such, the assessment of CIPN remains critically important in both research and clinic settings.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the validity of various patient-reported outcome measures (PROMs) with neurophysiological and sensory functional measures as the optimal method of CIPN assessment.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study evaluated participants treated with neurotoxic chemotherapy across 2 cohorts using a dual-study design. Participants commencing treatment were assessed prospectively at beginning of neurotoxic treatment, midtreatment, and at the end of treatment. Participants who completed treatment up to 5 years prior were assessed cross-sectionally and completed a single assessment time point. Participants were recruited from oncology centers in Australia from August 2015 to November 2022. Data analysis occurred from February to November 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Neurotoxic cancer treatment including taxanes, platinums, vinca-alkaloids, proteasome inhibitors, and thalidomide.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>CIPN was assessed via PROMs (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-CIPN20], Functional Assessment of Cancer Therapy\/Gynecological Cancer Group Neurotoxicity Questionnaire (FACT\/GOG-Ntx), and the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events [PRO-CTCAE]), neurological and neurophysiological assessment (Total Neuropathy Score and sural and tibial compound nerve amplitudes), and sensory measures (Grating orientation, Von Frey monofilament, and 2-point discrimination tasks). Core measurement properties of CIPN outcome measures were evaluated. Convergent and known-groups validity was assessed cross-sectionally following treatment completion, and responsiveness was evaluated prospectively during treatment. Neurological, neurophysiological, and sensory outcome measure scores were compared between those who reported high and low levels of CIPN symptoms using linear regressions.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 1033 participants (median [IQR] age, 61 [50-59] years; 676 female [65.4%]) were recruited to this study, incorporating 1623 assessments. PROMs demonstrated best ability to accurately assess CIPN (convergent validity), especially the PRO-CTCAE composite score (r<\/jats:italic>\u2009=\u20090.85; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and EORTC-CIPN20 (r<\/jats:italic>\u2009=\u20090.79; P<\/jats:italic>\u2009&amp;lt;\u2009.001). PROMS also demonstrated the best ability to discriminate between CIPN severity (known-groups validity) and to detect changes at onset of CIPN development (responsiveness), especially for EORTC-CIPN20 (d<\/jats:italic>\u2009=\u20090.67; 95% CI, 0.52-0.83), FACT\/GOG-Ntx (d<\/jats:italic>\u2009=\u20090.65; 95% CI, 0.49-0.81) and the PRO-CTCAE (d<\/jats:italic>\u2009=\u20090.83; 95% CI, 0.64-1.02). Other measures did not achieve threshold for convergent validity (\u03b1\u2009&amp;lt;\u20090.7). Neurophysiological and sensory measures did not demonstrate acceptable responsiveness. In regression models, neurological, neurophysiological, and sensory outcome measures were significantly impaired in participants who reported high levels of CIPN symptoms compared with those who reported low levels of CIPN symptoms.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of 1033 cancer patients, PROMs were the only measures to satisfy all 3 core measurement property criteria (convergent validity, known-groups validity, and responsiveness). These findings suggest that adoption of PROMs in clinical practice can equip clinicians with valuable information in assessing CIPN morbidity.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.24139","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T15:31:22Z","timestamp":1723217482000},"page":"e2424139","source":"Crossref","is-referenced-by-count":36,"title":["Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy"],"prefix":"10.1001","volume":"7","author":[{"given":"Tiffany","family":"Li","sequence":"first","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"Brain and Mind Centre, University of Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah C.","family":"Timmins","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"Neuroscience Research Australia, Sydney, Australia"},{"name":"Brain and Mind Centre, University of Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawaz M.","family":"Mahfouz","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"Brain and Mind Centre, University of Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Trinh","sequence":"additional","affiliation":[{"name":"Neuroscience Research Australia, Sydney, Australia"},{"name":"School of Clinical Medicine, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mizrahi","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of New South Wales, Sydney, Australia"},{"name":"The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[{"name":"Chris O\u2019Brien Lifehouse, Sydney, Australia"},{"name":"Sydney Medical School, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Harrison","sequence":"additional","affiliation":[{"name":"Chris O\u2019Brien Lifehouse, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Grimison","sequence":"additional","affiliation":[{"name":"Chris O\u2019Brien Lifehouse, Sydney, Australia"},{"name":"Sydney Medical School, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, University of New South Wales, Sydney, Australia"},{"name":"Prince of Wales Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Marx","sequence":"additional","affiliation":[{"name":"Sydney Adventist Hospital, Sydney, Australia"},{"name":"School of Medicine and Psychology, The Australian National University, Canberra, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Boyle","sequence":"additional","affiliation":[{"name":"Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wyld","sequence":"additional","affiliation":[{"name":"Cancer Care Services, Royal Brisbane and Women\u2019s Hospital, Faculty of Medicine, University of Queensland, Brisbane, Australia"},{"name":"Faculty of Medicine, University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Henderson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Royal Brisbane & Women\u2019s Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"King","sequence":"additional","affiliation":[{"name":"Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia"},{"name":"Faculty of Medicine and Health, Cancer Care Research Unit, Susan Wakil School of Nursing and Midwifery, The University of Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Baron-Hay","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Kiernan","sequence":"additional","affiliation":[{"name":"Neuroscience Research Australia, Sydney, Australia"},{"name":"Brain and Mind Centre, University of Sydney, Australia"},{"name":"Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rutherford","sequence":"additional","affiliation":[{"name":"The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council New South Wales, Sydney, Australia"},{"name":"Faculty of Medicine and Health, Cancer Care Research Unit, Susan Wakil School of Nursing and Midwifery, The University of Sydney, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Prince of Wales Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna B.","family":"Park","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"Chris O\u2019Brien Lifehouse, Sydney, Australia"},{"name":"Brain and Mind Centre, University of Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"issue":"3","key":"zoi240760r1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","article-title":"Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy.","volume":"125","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"zoi240760r2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer.","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi240760r3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/ene.12061","article-title":"Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.","volume":"20","author":"Argyriou","year":"2013","journal-title":"Eur J Neurol"},{"issue":"10","key":"zoi240760r4","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G","article-title":"Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas.","volume":"73","author":"Haim","year":"1994","journal-title":"Cancer"},{"issue":"3","key":"zoi240760r5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/hon.2706","article-title":"Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials.","volume":"38","author":"Li","year":"2020","journal-title":"Hematol Oncol"},{"issue":"10","key":"zoi240760r6","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/S2352-3026(18)30149-2","article-title":"Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.","volume":"5","author":"van de Donk","year":"2018","journal-title":"Lancet Haematol"},{"issue":"5","key":"zoi240760r7","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1200\/JOP.2012.000863","article-title":"Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.","volume":"9","author":"Speck","year":"2013","journal-title":"J Oncol Pract"},{"key":"zoi240760r8","article-title":"Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients.","author":"Boakye","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"zoi240760r9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.6004\/jnccn.2021.7026","article-title":"Chemotherapy-induced peripheral neurotoxicity in cancer survivors: predictors of long-term patient outcomes.","volume":"19","author":"Battaglini","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"zoi240760r10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3322\/caac.21204","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis.","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"zoi240760r11","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00520-019-05023-5","article-title":"Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity.","volume":"28","author":"Argyriou","year":"2020","journal-title":"Support Care Cancer"},{"issue":"6","key":"zoi240760r12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jnci\/djz011","article-title":"The National Cancer Institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy.","volume":"111","author":"Dorsey","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"zoi240760r13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1634\/theoncologist.2019-0489","article-title":"Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer survivors: a randomized controlled pilot trial.","volume":"25","author":"Lu","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"zoi240760r14","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1186\/s12885-021-09069-9","article-title":"Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.","volume":"21","author":"Sugimoto","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi240760r15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/1078155220959431","article-title":"Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: a systematic review.","volume":"27","author":"Bailey","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"zoi240760r16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00520-017-4013-0","article-title":"Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.","volume":"26","author":"Kleckner","year":"2018","journal-title":"Support Care Cancer"},{"issue":"3","key":"zoi240760r17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"zoi240760r18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","article-title":"Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.","volume":"9","author":"Postma","year":"1998","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi240760r19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools.","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"issue":"11","key":"zoi240760r20","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s00520-017-3772-y","article-title":"Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.","volume":"25","author":"McCrary","year":"2017","journal-title":"Support Care Cancer"},{"issue":"1","key":"zoi240760r21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdt409","article-title":"Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.","volume":"25","author":"Alberti","year":"2014","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi240760r22","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1007\/s00520-020-05299-y","article-title":"Taxane-induced peripheral neuropathy: differences in patient report and objective assessment.","volume":"28","author":"Timmins","year":"2020","journal-title":"Support Care Cancer"},{"issue":"11","key":"zoi240760r23","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/annonc\/mdx491","article-title":"Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.","volume":"28","author":"Park","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi240760r24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments.","volume":"13","author":"Di Maio","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"zoi240760r25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial.","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi240760r26","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1007\/s11136-022-03154-7","article-title":"Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.","volume":"31","author":"Li","year":"2022","journal-title":"Qual Life Res"},{"issue":"8","key":"zoi240760r27","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.clinph.2020.02.028","article-title":"Electrophysiological and phenotypic profiles of taxane-induced neuropathy.","volume":"131","author":"Timmins","year":"2020","journal-title":"Clin Neurophysiol"},{"issue":"2","key":"zoi240760r28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00520-020-05543-5","article-title":"Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).","volume":"29","author":"Albany","year":"2021","journal-title":"Support Care Cancer"},{"issue":"1","key":"zoi240760r29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.annonc.2019.09.006","article-title":"Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy.","volume":"31","author":"Beijers","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi240760r30","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41416-021-01471-1","article-title":"Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial.","volume":"125","author":"M\u00fcller","year":"2021","journal-title":"Br J Cancer"},{"issue":"20","key":"zoi240760r31","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"zoi240760r32","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"issue":"6","key":"zoi240760r33","first-page":"741","article-title":"Psychometric evaluation of the functional assessment of cancer therapy\/gynecologic oncology group-neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"zoi240760r34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi240760r35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).","volume":"18","author":"Basch","year":"2021","journal-title":"Clin Trials"},{"issue":"2","key":"zoi240760r36","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi240760r37","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","article-title":"Total neuropathy score: validation and reliability study.","volume":"53","author":"Cornblath","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"zoi240760r38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","article-title":"Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity.","volume":"11","author":"Cavaletti","year":"2006","journal-title":"J Peripher Nerv Syst"},{"issue":"6","key":"zoi240760r39","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/jnnp.37.6.647","article-title":"Sensory conduction of the sural nerve in polyneuropathy.","volume":"37","author":"Burke","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"zoi240760r41","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1212\/WNL.44.12.2361","article-title":"The limit of tactile spatial resolution in humans: grating orientation discrimination at the lip, tongue, and finger.","volume":"44","author":"Van Boven","year":"1994","journal-title":"Neurology"},{"issue":"3","key":"zoi240760r42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pain.2006.01.041","article-title":"Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values.","volume":"123","author":"Rolke","year":"2006","journal-title":"Pain"},{"issue":"7","key":"zoi240760r43","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/jnnp.2007.139220","article-title":"Revising two-point discrimination assessment in normal aging and in patients with polyneuropathies.","volume":"79","author":"van Nes","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"zoi240760r44","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11136-012-0344-y","article-title":"ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research.","volume":"22","author":"Reeve","year":"2013","journal-title":"Qual Life Res"},{"issue":"7","key":"zoi240760r45","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","article-title":"The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes.","volume":"63","author":"Mokkink","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"zoi240760r46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jpainsymman.2016.12.342","article-title":"Chemotherapy-induced neuropathy in cancer survivors.","volume":"54","author":"Miaskowski","year":"2017","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"zoi240760r47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12885-019-5302-4","article-title":"Are we mis-estimating chemotherapy-induced peripheral neuropathy? analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.","volume":"19","author":"Molassiotis","year":"2019","journal-title":"BMC Cancer"},{"issue":"7","key":"zoi240760r48","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1007\/s00520-022-07024-3","article-title":"Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy.","volume":"30","author":"Mizrahi","year":"2022","journal-title":"Support Care Cancer"},{"key":"zoi240760r49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102241","article-title":"Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced peripheral neuropathy (CIPN).","volume":"99","author":"Hertz","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"zoi240760r50","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S1470-2045(18)30093-7","article-title":"3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.","volume":"19","author":"Iveson","year":"2018","journal-title":"Lancet Oncol"},{"issue":"33","key":"zoi240760r51","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1200\/JCO.21.02962","article-title":"Oxaliplatin (3 months v 6 months) With 6 Months of fluoropyrimidine as adjuvant therapy in patients with stage II\/III colon cancer: KCSG CO09-07.","volume":"40","author":"Kim","year":"2022","journal-title":"J Clin Oncol"},{"issue":"29","key":"zoi240760r52","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.21.02628","article-title":"Final analysis of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine-based therapy in patients with stage III colon cancer: the randomized phase III ACHIEVE trial.","volume":"40","author":"Yoshino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi240760r53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1023\/A:1008345613594","article-title":"Grading of chemotherapy-induced peripheral neuropathy.","volume":"11","author":"Postma","year":"2000","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi240760r54","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","article-title":"Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties.","volume":"15","author":"Griffith","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"zoi240760r55","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jcph.1559","article-title":"Personalized management of chemotherapy-induced peripheral neuropathy based on a patient reported outcome: CALGB 40502 (Alliance).","volume":"60","author":"Sharma","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"zoi240760r56","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(23)00157-2","article-title":"Setting international standards in analyzing patient-reported outcomes and quality of life endpoints in cancer clinical trials-innovative medicines initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.","volume":"24","author":"Pe","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi240760r57","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline.","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi240760r58","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1188\/17.ONF.580-588","article-title":"The content validity of a chemotherapy-induced peripheral neuropathy patient-reported outcome measure.","volume":"44","author":"Lavoie Smith","year":"2017","journal-title":"Oncol Nurs Forum"},{"issue":"11","key":"zoi240760r59","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s11136-017-1626-1","article-title":"Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).","volume":"26","author":"Kieffer","year":"2017","journal-title":"Qual Life Res"},{"issue":"7","key":"zoi240760r60","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1212\/WNL.0000000000012300","article-title":"Prospective evaluation of health care provider and patient assessments in chemotherapy-induced peripheral neurotoxicity.","volume":"97","author":"Alberti","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"zoi240760r61","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jpainsymman.2019.07.021","article-title":"Optimizing clinical screening for chemotherapy-induced peripheral neuropathy.","volume":"58","author":"McCrary","year":"2019","journal-title":"J Pain Symptom Manage"},{"issue":"21","key":"zoi240760r62","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.23.00903","article-title":"Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (Alliance N1048).","volume":"41","author":"Basch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi240760r63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41397-019-0093-1","article-title":"Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy.","volume":"19","author":"Hertz","year":"2019","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"zoi240760r64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.6004\/jnccn.2022.7074","article-title":"Patient-reported outcome measures in chemotherapy-induced peripheral neurotoxicity: defining minimal and clinically important changes.","volume":"21","author":"Li","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi240760r65","first-page":"17","article-title":"Framework To guide the collection and use of patient-reported outcome measures in the learning healthcare system.","volume":"5","author":"Franklin","year":"2017","journal-title":"EGEMS (Wash DC)"},{"issue":"3","key":"zoi240760r66","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11136-018-2048-4","article-title":"Implementing patient-reported outcome measures in clinical practice: a companion guide to the ISOQOL user\u2019s guide.","volume":"28","author":"Chan","year":"2019","journal-title":"Qual Life Res"},{"issue":"24","key":"zoi240760r67","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial.","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"issue":"17","key":"zoi240760r68","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.3390\/cancers15174216","article-title":"Studies to assess the utility of serum neurofilament light chain as a biomarker in chemotherapy-induced peripheral neuropathy.","volume":"15","author":"Cavaletti","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"zoi240760r69","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/j.pain.0000000000002840","article-title":"Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer.","volume":"164","author":"Mortensen","year":"2023","journal-title":"Pain"},{"issue":"3","key":"zoi240760r70","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"zoi240760r71","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.clinph.2010.06.025","article-title":"Current status on electrodiagnostic standards and guidelines in neuromuscular disorders.","volume":"122","author":"Fuglsang-Frederiksen","year":"2011","journal-title":"Clin Neurophysiol"},{"issue":"12","key":"zoi240760r72","first-page":"1361","article-title":"Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings.","volume":"90","author":"Argyriou","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"zoi240760r73","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2008.19.3425","article-title":"Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.","volume":"27","author":"Park","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi240760r74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.PHM.0000069198.47377.72","article-title":"Sural and saphenous 14-cm antidromic sensory nerve conduction studies.","volume":"82","author":"Buschbacher","year":"2003","journal-title":"Am J Phys Med Rehabil"},{"key":"zoi240760r40","doi-asserted-by":"crossref","DOI":"10.1891\/9781617050053","volume-title":"Practical approach to electromyography: an illustrated guide for clinicians","author":"Siao","year":"2011"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822154\/li_2024_oi_240760_1722613167.91392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T15:31:53Z","timestamp":1723217513000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.24139","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}